Clinical trials: Tamoxifen
Pain, Discomfort
TAmoxifen Versus LIdocaine Cream. A Randomized Clinical Trial for Reducing Pain and Discomfort During Mammography
This is a double-blind placebo-controlled randomized clinical trial to test the use of tamoxifen or lidocaine for diminishing the pain and discomfort while performing mammography, intending to include 450 patients distributed…
- Trial name
- TALI (NCT02801786)
- Testing
- Lidocaine, Tamoxifen
- Where
- Brazil
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Universidade Federal de Goias
Schizophrenia in Post Menopausal Women
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women
The efficacy of raloxifene versus placebo was compared over a six-month period, as an adjuvant treatment of the negative symptoms of schizophrenia in a group of 80 post-menopausal women.
- Trial name
- NCT01573637
- Testing
- Raloxifene
- Where
- 3 sites in Spain
- Volunteers
- 78 people
- Sponsor
- Fundació Sant Joan de Déu
Breast Cancer
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00949598
- Testing
- letrozole, tamoxifen citrate
- Where
- France
- Volunteers
- 177 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Vasomotor Symptoms (VMS)
Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor
This is a Phase 2 proof-of-concept (POC) study designed to determine the effectiveness of Q-122 for the treatment of Vasomotor Symptoms (VMS) versus placebo.
- Trial name
- NCT03518138
- Testing
- Q-122
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 132 people
- Sponsor
- Que Oncology
Breast Cancer
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
The purpose of this multi-centre, randomised, double-blind, parallel-group study is to compare efficacy and safety between anastrozole and tamoxifen in pre- and post-operative administration under goserelin acetate treatment for…
- Trial name
- NCT00605267
- Testing
- Tamoxifen, Anastrazole (Arimidex), Goserelin acetate (Zoladex)
- Where
- 4 sites in Japan
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Breast Neoplasms
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with…
- Trial name
- NCT02057133
- Testing
- LY2835219, Letrozole, Anastrozole
- Where
- 13 sites in United States
- Volunteers
- 198 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Tamoxifen Pharmacogenetics and Clinical Effects
The purpose of this research is to try to identify which women who take tamoxifen are likely to suffer from hot flashes or are more likely to have other side effects or benefits from the drug.
- Trial name
- NCT00228930
- Testing
- Tamoxifen (pharmacodynamic analysis)
- Where
- 2 sites in United States
- Volunteers
- 297 people
- Sponsor
- National Institute of General Medical Sciences (NIGMS)
Duchenne Muscular Dystrophy
Tamoxifen in Duchenne Muscular Dystrophy
A randomised, double blind, placebo controlled, 48-week clinical trial with a core population (group A) of 79 ambulant 6.5 to 12 years old Duchenne's muscular dystrophy (DMD) patients that are under stable standard treatment of…
- Trial name
- TAMDMD (NCT03354039)
- Testing
- Tamoxifen
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 93 people
- Sponsor
- University Hospital, Basel, Switzerland
Breast Cancer Female, Healthy Female
Breast Cancer & Antiestrogenic Therapy & Brain
The study aims to investigate the effect of anti-estrogenic therapy in breast cancer patients on neural reward processing, psychosexual health, and quality of life, in reproductive vs. menopausal women.
- Conditions
- Breast Cancer Female, Healthy Female, Menopause, Anti-estrogenic Therapy
- Trial name
- NCT06346457
- Testing
- Tamoxifen, Letrozole, Letrozole + GnRH
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- International Research Training Group 2804
Breast Cancer
Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Estrogen can stimulate the growth of breast cancer cells.
- Trial name
- NCT00003857
- Testing
- tamoxifen citrate, adjuvant therapy, radiation therapy
- Where
- 369 sites in United States, Canada
- Volunteers
- 636 people
- Sponsor
- Radiation Therapy Oncology Group
Brain and Central Nervous System Tumors
Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Tamoxifen may kill tumor cells by blocking the enzymes necessary for cell growth.
- Trial name
- NCT00024336
- Testing
- tamoxifen citrate, radiation therapy
- Where
- 22 sites in Ireland, United Kingdom
- Sponsor
- Children's Cancer and Leukaemia Group
Breast Cancer
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the…
- Trial name
- NCT00290745
- Testing
- letrozole, tamoxifen citrate, conventional surgery
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of California, San Francisco
Breast Cancer Female
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
This is a prospective multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer.
- Trial name
- POWER (NCT04272801)
- Testing
- tamoxifen, letrozole, anastrozole, or exemestane, Patient reported outcomes
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- Shayna Showalter, MD
Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
This randomized phase II trial is studying 4-hydroxytamoxifen to see how well it works compared with tamoxifen citrate in treating women with newly diagnosed ductal breast carcinoma in situ.
- Trial name
- NCT00952731
- Testing
- afimoxifene, tamoxifen citrate
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Northwestern University
Breast Cancer
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent…
- Trial name
- DATA (NCT00301457)
- Testing
- Anastrozole
- Where
- 67 sites in Netherlands
- Volunteers
- 1,914 people
- Sponsor
- Maastricht University Medical Center
Osteoporosis, Postmenopausal
Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal…
- Trial name
- NCT00790101
- Testing
- Risedronate, Raloxifene
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sanofi
Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
This is a non-randomized, open-label, single-arm, multicenter, phase II study of palbociclib in combination with tamoxifen in women with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anticancer…
- Conditions
- Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor
- Trial name
- NCT02668666
- Testing
- Palbociclib, Tamoxifen
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Oana Danciu, MD
High Background Uptake on MBI
Impact of Low-dose Tamoxifen on BPU
The study will examine whether changes in background parenchymal uptake (BPU) on molecular breast imaging (MBI) can be induced by short-term use of low-dose tamoxifen.
- Trial name
- NCT02979301
- Testing
- Tamoxifen
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer
RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. Tamoxifen may be effective in reducing breast density by decreasing estrogen levels.
- Trial name
- NCT00086749
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Breast Cancer
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
The utilization of tamoxifen is considerably high in Indonesia, with about 170,000 tamoxifen prescriptions filed in 2015. It is metabolized by the enzyme CYP2D6, resulting in its active metabolite, endoxifen, which has been…
- Trial name
- NCT05501158
- Testing
- Tamoxifen
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- Nalagenetics Pte Ltd